MapLight Therapeutics, Inc.

MPLT Nasdaq CIK: 0001770069

Company Information

Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting companyEmerging growth company
State of Incorporation DE
Business Address 800 CHESAPEAKE DRIVE, REDWOOD CITY, CA, 94063
Mailing Address 800 CHESAPEAKE DRIVE, REDWOOD CITY, CA, 94063
Phone 650-839-4360
Fiscal Year End 1231
EIN 832163243

Recent SEC Filings

Form Type Date Filed Document
10-K Annual financial report March 26, 2026 View on SEC
8-K Current report of material events March 26, 2026 View on SEC
4 Insider stock transaction report February 24, 2026 View on SEC
4 Insider stock transaction report February 20, 2026 View on SEC
4 Insider stock transaction report February 18, 2026 View on SEC
SCHEDULE 13G Passive beneficial ownership (>5%) February 17, 2026 View on SEC
SCHEDULE 13G Passive beneficial ownership (>5%) February 17, 2026 View on SEC
4 Insider stock transaction report February 12, 2026 View on SEC
4 Insider stock transaction report February 12, 2026 View on SEC
4 Insider stock transaction report February 9, 2026 View on SEC

IPO Filings

S-1 September 19, 2025
  • Portfolio of brain-targeted drugs addressing major neurological conditions (autism, Parkinson’s, schizophrenia, Alzheimer’s psychosis) with a late-stage candidate (ML-007C-MA).
  • Innovative 'brain circuit repair' approach for precision treatment, potentially offering fewer side effects than existing therapies.
View Analysis

Annual Reports

10-K March 26, 2026
  • Proprietary AI-driven 'MapLight Circuit-Based Drug Discovery' platform.
  • Lead drug candidate ML-007C-MA targeting schizophrenia and Alzheimer’s-related psychosis.
View Analysis

Insider Trading

STRONG SELL 3 insiders 17 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2834)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.